Navigation Links
ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
Date:9/9/2008

mer forecasts, our failure to meet

customers' purchase order and quality requirements, supply shortages,

production delays, changes in the markets for customers' products,

introduction timing and acceptance of our new products scheduled for fiscal

year 2009, and introduction of competitive products and other factors beyond our control, could result in a materially different revenue outcome and/or in

our failure to achieve the revenue levels we expect for fiscal 2009. A more

complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set

forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to
time, and you should consider each of those factors when evaluating the

forward-looking statements.

ThermoGenesis Corp.

Web site: http://www.thermogenesis.com

Contact: Investor Relations

+1-916-858-5107, or

ir@thermogenesis.com


'/>"/>
SOURCE ThermoGenesis Corp.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal Year 2007 on September 12, 2007
2. ThermoGenesis Corp. Reports Fourth Quarter and Fiscal Year 2007 Results
3. ThermoGenesis Corp. to Present at 2007 Global Life Sciences Conference on Thursday, September 27, 2007
4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007
5. ThermoGenesis Corp. to Announce Second Quarter Fiscal 2008 Results on February 6, 2008
6. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
7. ThermoGenesis Corp. Announces Voluntary Recall of Selected Lots of AXP Bag Sets
8. ThermoGenesis Subsidiary Vantus Announces Stem Cell Agreement With UC Davis Center For Equine Health
9. ThermoGenesis Names Dr. Mahendra Rao to Board of Directors
10. ThermoGenesis Announces Receipt of CE Mark for MarrowXpress(TM)
11. ThermoGenesis Announces FDA Authorization to Market MarrowXpress(TM) (MXP(TM))
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 2Breakthrough TriPollar Technology- the Most Advanced Anti-Aging Solution- to Launch into High Growth Brazilian Market for Aesthetic Procedures 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 2RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 3RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 4RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 5RE-COVER Study Evaluating Dabigatran Etexilate Met Primary Outcome for the Six-Month Treatment of Patients with Acute Venous Thromboembolism (VTE) 6Alberta companies delivering new products to the health & medical marketplace 2JourneyLite of Houston Now Offering Sleeve Gastrectomy 2
Other Biology Technology:Covaris Installed Instrument Base Reaches 500 Units 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 2Shasta Regional Medical Center Awarded Full Accreditation from the Joint Commission 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 2Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 3Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 4Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 5Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 6Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 7Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 8Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 9Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 10Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 11Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 12Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 13Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 14Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 15Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 16Interim Report for the Period 1 January - 30 September 2008 (Unaudited) 17